As previously reported, Ladenburg initiated coverage of Novocure (NVCR) with a Buy rating and $30 price target The firm cites a positive outlook for Optune Gio to retain “healthy market share” in glioblastoma, a path to profitability based on uptake of Optune Lua in treatment of second-line non small cell lung cancer and evidence supporting Tumor Treating Fields as a platform technology for various solid tumors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR: